SynthesisJournal of the Egyptian National Cancer Institute2026

Comparative efficacy and safety of first, second, and third-generation EGFR tyrosine kinase inhibitors in treatment-naïve EGFR-mutant advanced non-small cell lung cancer: a systematic review and network meta-analysis of randomized controlled trials.

Sumit Mahato et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.